21 research outputs found
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation
The p53 tumor suppressor is inhibited and destabilized by Mdm2. However, under stress conditions, this downregulation is relieved, allowing the accumulation of biologically active p53. Recently we showed that c-Abl is important for p53 activation under stress conditions. In response to DNA damage, c-Abl protects p53 by neutralizing the inhibitory effects of Mdm2. In this study we ask whether this neutralization involves a direct interplay between c-Abl and Mdm2, and what is the contribution of the c-Abl kinase activity? We demonstrate that the kinase activity of c-Abl is required for maintaining the basal levels of p53 expression and for achieving maximal accumulation of p53 in response to DNA damage. Importantly, c-Abl binds and phosphorylates Mdm2 in vivo and in vitro. We characterize Hdm2 (human Mdm2) phosphorylation at Tyr394. Substitution of Tyr394 by Phe394 enhances the ability of Mdm2 to promote p53 degradation and to inhibit its transcriptional and apoptotic activities. Our results suggest that phosphorylation of Mdm2 by c-Abl impairs the inhibition of p53 by Mdm2, hence defining a novel mechanism by which c-Abl activates p53
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy
The epidermal growth factor receptor (EGFR) frequently associates with cancer and already serves as a target for therapy. We report that inflammatory cytokines and ultraviolet (UV) irradiation respectively induce transient or sustained phosphorylation of EGFR. Subsequently, EGFR internalizes via a Clathrin-mediated process. In cytokine-stimulated cells, EGFR recycles back to the cell surface, whereas in irradiated cells it arrests in Rab5-containing endosomes. Under both conditions, receptor internalization is instigated by the p38 stress-induced kinase. The underlying mechanism entails phosphorylation of EGFR at a short segment (amino acids 1002–1022) containing multiple serines and threonines, as well as phosphorylation of two Rab5 effectors, EEA1 and GDI. Like UV irradiation, a chemotherapeutic agent activates p38 and accelerates receptor internalization. We demonstrate that abrogating EGFR internalization reduces the efficacy of chemotherapy-induced cell death. Hence, by preventing EGFR-mediated survival signaling, the internalization route we uncovered enhances the cytotoxic effect of drugs like cis-platinum, which may underlie interactions between chemotherapy and EGFR-targeting drugs
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer
Breast cancer subtypes display distinct biological traits that influence
their clinical behavior and response to therapy. Recent studies have
highlighted the importance of chromatin structure regulators in
tumorigenesis. The RNF20-RNF40 E3 ubiquitin ligase complex
monoubiquitylates histone H2B to generate H2Bub1, while the
deubiquitinase (DUB) USP44 can remove this modification. We found that
RNF20 and RNF40 expression and global H2Bub1 are relatively low, and
USP44 expression is relatively high, in basal-like breast tumors
compared with luminal tumors. Consistent with a tumor-suppressive role,
silencing of RNF20 in basal-like breast cancer cells increased their
proliferation and migration, and their tumorigenicity and metastatic
capacity, partly through upregulation of inflammatory cytokines. In
contrast, in luminal breast cancer cells, RNF20 silencing reduced
proliferation, migration and tumorigenic and metastatic capacity, and
compromised estrogen receptor transcriptional activity, indicating a
tumor-promoting role. Notably, the effects of USP44 silencing on
proliferation and migration in both cancer subtypes were opposite to
those of RNF20 silencing. Hence, RNF20 and H2Bub1 have contrasting roles
in distinct breast cancer subtypes, through differential regulation of
key transcriptional programs underpinning the distinctive traits of each
subtype
Predicting and affecting response to cancer therapy based on pathway-level biomarkers
Predicting an individual's response to therapy is an important goal for precision medicine. Here, the authors use an algorithm that takes into account the interaction type and directionality of signalling pathways in protein–protein interactions and find that their pathway analysis can predict essential genes, which may be a target for therapy
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding
The tumor suppressor gene 101 (tsg101) regulates vesicular trafficking processes in yeast and mammals. We report a novel protein, Tal (Tsg101-associated ligase), whose RING finger is necessary for multiple monoubiquitylation of Tsg101. Bivalent binding of Tsg101 to a tandem tetrapeptide motif (PTAP) and to a central region of Tal is essential for Tal-mediated ubiquitylation of Tsg101. By studying endocytosis of the epidermal growth factor receptor and egress of the human immunodeficiency virus, we conclude that Tal regulates a Tsg101-associated complex responsible for the sorting of cargo into cytoplasm-containing vesicles that bud at the multivesicular body and at the plasma membrane
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.National Institutes of Health (U.S.) (Grant K99 CA169512)National Cancer Institute (U.S.) (Koch Institute Support Grant P30-CA14051)Virginia and D.K. Ludwig Fund for Cancer ResearchAmerican Association for Cancer ResearchHoward Hughes Medical InstituteLeukemia & Lymphoma Society of AmericaUnited States. Department of Defense (Fellowship W81XWH-10-1-0062